BACKGROUND: During and after systemic therapy, patients with high risk and advanced melanoma experience challenges regarding cancer-related symptoms, treatment-related adverse events, and an impact of these symptoms on their physical and psychosocial well-being. Few studies have investigated the specific needs of these patients and the potential role of eHealth applications in meeting those needs. OBJECTIVE: To explore the supportive care and information needs of high risk and advanced melanoma patients, and how these needs can be supported by eHealth applications. METHODS: In this qualitative study, semi-structured interviews with high risk and advanced melanoma patients during or after systemic treatment were conducted to understand their...
Background: Although many cancer survivors could benefit from supportive care, they often do not uti...
The prevalence and burden of chronic diseases, including cancer, are escalating worldwide. New model...
Abstract Purpose Development of innovative drugs for melanoma is occurring rapidly. Incremental gain...
Background During and after systemic therapy, patients with high risk and advanced melanoma experien...
BackgroundSince treatment with immune checkpoint inhibitors (ICIs) is becoming standard therapy for ...
Aims and objectives: To gain insight into cancer survivors' needs towards an eHealth application mon...
Background: Melanoma is the fourth most commonly diagnosed cancer in Australia. Up to 75% of melanom...
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in ove...
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in ove...
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in ove...
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in ove...
Purpose: Understanding the supportive care and unmet care needs of patients with melanoma is essenti...
Background: The shift from inpatient to outpatient and community cancer care means that more patient...
Cancer survivorship is increasing year on year due to an aging population and improvements in cancer...
Purpose To examine patients’ experiences regarding the impact of support given by a mobile applicati...
Background: Although many cancer survivors could benefit from supportive care, they often do not uti...
The prevalence and burden of chronic diseases, including cancer, are escalating worldwide. New model...
Abstract Purpose Development of innovative drugs for melanoma is occurring rapidly. Incremental gain...
Background During and after systemic therapy, patients with high risk and advanced melanoma experien...
BackgroundSince treatment with immune checkpoint inhibitors (ICIs) is becoming standard therapy for ...
Aims and objectives: To gain insight into cancer survivors' needs towards an eHealth application mon...
Background: Melanoma is the fourth most commonly diagnosed cancer in Australia. Up to 75% of melanom...
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in ove...
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in ove...
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in ove...
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in ove...
Purpose: Understanding the supportive care and unmet care needs of patients with melanoma is essenti...
Background: The shift from inpatient to outpatient and community cancer care means that more patient...
Cancer survivorship is increasing year on year due to an aging population and improvements in cancer...
Purpose To examine patients’ experiences regarding the impact of support given by a mobile applicati...
Background: Although many cancer survivors could benefit from supportive care, they often do not uti...
The prevalence and burden of chronic diseases, including cancer, are escalating worldwide. New model...
Abstract Purpose Development of innovative drugs for melanoma is occurring rapidly. Incremental gain...